These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20532049)

  • 21. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.
    Boik JC; Newman RA; Boik RJ
    Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.
    Yadav B; Wennerberg K; Aittokallio T; Tang J
    Comput Struct Biotechnol J; 2015; 13():504-13. PubMed ID: 26949479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mathematical formulation of additivity for antimicrobial agents.
    Boucher AN; Tam VH
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):319-25. PubMed ID: 16626903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the Effect of Mycotoxin Combinations: Which Mathematical Model Is (the Most) Appropriate?
    Kifer D; Jakšić D; Šegvić Klarić M
    Toxins (Basel); 2020 Feb; 12(3):. PubMed ID: 32121330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.
    Afeltra J; Vitale RG; Mouton JW; Verweij PE
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1335-43. PubMed ID: 15047538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the rocuronium-vecuronium interaction on tetanic fade based on a generalized response surface model with varying relative potencies.
    Lee JH; Lee SI; Lee SC; Cho WJ
    Korean J Anesthesiol; 2009 May; 56(5):559-566. PubMed ID: 30625788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental designs for detecting synergy and antagonism between two drugs in a pre-clinical study.
    Sperrin M; Thygesen H; Su TL; Harbron C; Whitehead A
    Pharm Stat; 2015; 14(3):216-25. PubMed ID: 25810342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fitting models for the joint action of two drugs using SAS.
    Whitehead A; Whitehead J; Todd S; Zhou Y; Smith MK
    Pharm Stat; 2008; 7(4):272-84. PubMed ID: 17979217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic and antagonistic effects of immunomodulatory drugs on the action of antifungals against
    Tome M; Zupan J; Tomičić Z; Matos T; Raspor P
    PeerJ; 2018; 6():e4999. PubMed ID: 29915703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.
    Tam VH; Schilling AN; Lewis RE; Melnick DA; Boucher AN
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4315-21. PubMed ID: 15504858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.
    Meletiadis J; te Dorsthorst DT; Verweij PE
    Int J Antimicrob Agents; 2006 Nov; 28(5):439-49. PubMed ID: 17055706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CombiTool--a new computer program for analyzing combination experiments with biologically active agents.
    Dressler V; Müller G; Sühnel J
    Comput Biomed Res; 1999 Apr; 32(2):145-60. PubMed ID: 10337496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators.
    Repash EM; Pensabene KM; Palenchar PM; Eggler AL
    Front Pharmacol; 2021; 12():686201. PubMed ID: 34163365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response envelope analysis for quantitative evaluation of drug combinations.
    Du D; Chang CH; Wang Y; Tong P; Chan WK; Chiu Y; Peng B; Tan L; Weinstein JN; Lorenzi PL
    Bioinformatics; 2019 Oct; 35(19):3761-3770. PubMed ID: 30851108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A semiparametric response surface model for assessing drug interaction.
    Kong M; Lee JJ
    Biometrics; 2008 Jun; 64(2):396-405. PubMed ID: 17900314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of drug combination effect using a Bliss independence dose-response surface model.
    Liu Q; Yin X; Languino LR; Altieri DC
    Stat Biopharm Res; 2018; 10(2):112-122. PubMed ID: 30881603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction.
    Lee JJ; Kong M
    Stat Biopharm Res; 2009 Feb; 1(1):4-17. PubMed ID: 20037663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergy evaluation of non-normalizable dose-response data: Generalization of combination index for the linear effect of drugs.
    Novotný B; Nagy M; Kurin E
    Pharm Stat; 2021 Nov; 20(6):982-989. PubMed ID: 33764621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines.
    Roell KR; Reif DM; Motsinger-Reif AA
    Front Pharmacol; 2017; 8():158. PubMed ID: 28473769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a three-drug nonlinear mixture response model.
    Brun YF; Greco WR
    Front Biosci (Schol Ed); 2010 Jan; 2(2):454-67. PubMed ID: 20036961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.